NCT04696120 is a Phase 2 clinical trial of Apixaban in Heart Failure, sponsored by Korea University Guro Hospital.

Who is sponsoring NCT04696120?

NCT04696120 is sponsored by Korea University Guro Hospital.

What drugs are being tested in NCT04696120?

Interventions in NCT04696120: Apixaban, Placebo.

What condition does NCT04696120 study?

NCT04696120 studies Heart Failure, Sinus Rhythm, Cerebrovascular Disease.

Is NCT04696120 still recruiting?

NCT04696120 is currently status unknown. Last updated 20 January 2021.

Last reviewed 2021-01-20 · How we verify

NCT04696120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial

Status unknown Phase 2 Last updated 20 January 2021

What this trial tests

Phase 2 trial testing Apixaban in Heart Failure in 200 participants. Status unknown.

Timeline

2 March 2021

Primary endpoint
30 August 2022

28 February 2023

Quick facts

Lead sponsor	Korea University Guro Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	200
Start date	2 March 2021
Primary completion	30 August 2022
Estimated completion	28 February 2023
Sites	10 locations across South Korea

Drugs / interventions tested

Apixaban (apixaban) — full drug profile →
Placebo

Conditions studied

Heart Failure — all drugs for Heart Failure →
Sinus Rhythm — all drugs for Sinus Rhythm →
Cerebrovascular Disease — all drugs for Cerebrovascular Disease →

Sponsor

Korea University Guro Hospital

Who can join

19 and older, any sex, with Heart Failure or Sinus Rhythm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

objectives: The primary aim of APIXBRAIN-HF Trial is to explore the effects of apixaban on brain protection in patients with sinus rhythm and heart failure Primary / Secondary Endpoint 1. New occurrence of brain pathology 1) Cortical cerebral microinfarcts 2) Silent lacunar infarction 3)Progression of white matter hyperintensities 2. Secondary endpoint 1) The change of cognitive function evaluated by MMSE-2 2) Individual variable of primary endpoint 3. Safety Endpoint Evaluation 1) Cerebral microbleeds on imaging

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns.
Baker AD, Schwamm LH, Sanborn DY, Furie K, et al · · 2022 · cited 9× · PMID 35086361 · DOI 10.1161/strokeaha.121.036706

Verify or expand the search:

Other trials of Apixaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Korea University Guro Hospital trials

Trials by the same sponsor.

NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04696120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
Last refreshed: 20 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing